ANAVEX LIFE SCIENCES CORP. — Director's Dealing 2020

Jan 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK: 0001314052
Period of Report: 2020-01-06

Reporting Person: MISSLING CHRISTOPHER U (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-06	Stock Option (Right to Buy)	$2.96	A	550000	Acquired	2030-01-06	Common Stock (550000)	Direct

Footnotes

F1: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome.